Zantac Patients with Cancer Claims – Mississippi Lawyers
If You Took Zantac Regularly, You Could Have Been Exposed to a Cancer-Causing
Chemical. Here’s What You Should Know.
If you typically use Zantac or generic heartburn medications with the active
ingredient ranitidine, you may notice an empty space on the shelves next
time you visit the pharmacy. That’s because the FDA published a
total recall of these products at the beginning of April 2020.
For the last 6 months, ranitidine has been the focus of multiple experiments
after a third-party lab blew the whistle on Zantac. They alleged
the drug created a carcinogen, N-nitrosodimethylamine (NDMA), when it broke down in stomach-similar conditions. Drugmakers including
current Zantac owner Sanofi denied this claim, suggesting the batch the
lab used was contaminated. They pulled the medication from stores temporarily
to assess manufacturing conditions and identify potential points of contamination.
Though initial FDA testing failed to find the NDMA levels reported by the
whistleblower, continued examination of the drug confirmed the problem
was widespread, and not due to contamination. In early 2020, the FDA concluded
Zantac and other ranitidine-based drugs are likely to expose patients to
a cancer-causing substance.
Recall Information for Zantac Users
Long-term users of Zantac and its generics should take note of the drug’s
recent recall for multiple reasons. First, because the FDA recommends
you stop using the drug and talk to your doctor about other options.
Second, because if you have been diagnosed with cancer or develop the disease,
you may have a claim against the companies involved in putting this drug
on the market. Though ranitidine has been sold since the 1980s, no company in the pharmaceutical
supply chain noticed or reported the risk of NDMA contamination in these
drugs. For patients left to discover the danger through a cancer diagnosis,
we are here to help you pursue justice.
Call Richard Schwartz & Associates, P.A. at (601) 869-0696 or send an online message if you think you have a claim. We can sit down with you in a free consultation
to determine your legal options.
When Ranitidine and Zantac Can Be Dangerous
Unlike many cases involving drug contamination, the dangers linked with
Zantac were not confined to certain batches that were poorly manufactured.
In fact, the NDMA exposure these drugs may cause cannot be prevented.
After continued testing, researchers found that the ranitidine molecule
includes all the chemical components of NDMA. When it begins to decay,
the dangerous substance is one of its byproducts.
The danger is so widespread because ranitidine decay occurs in common scenarios.
The drug may begin to break down when:
- In storage at room temperature.
- Exposed to higher temperatures, such as those averaged during distribution
and consumer use
- The product gets wet
The longer ranitidine-based medications spend on the shelf, the higher
the levels of NDMA they are likely to contain. Being stored in high-temperature
locations accelerates the molecule’s decay.
The good news, if there is any, is that NDMA exposure does not cause cancer
right away. When exposed to relatively high amounts over a long period
of time, patients’ risk begins to increase. This means short-term
users likely do not have to worry about NDMA-induced cancers. However,
patients who used the drug consistently may have experienced dangerous
NDMA levels in their blood.
What You Should Know About NDMA
NDMA is a naturally occurring material, and humans are exposed to small
(likely harmless) amounts in day-to-day life. However, it is listed as a “probable carcinogen” by the International Agency for Research on Cancer. NDMA is among
a class of chemicals called “N-nitrosamines,” many of which are
known for causing cancer. Because it has the ability to interfere with and change DNA, NDMA may
cause genetic mutations that can lead people to develop cancer. When the
chemical enters the bloodstream, it has the potential to cause widespread
damage. This is the situation many Zantac users unknowingly faced.
It is likely scientists will dig deeper into the risks of NDMA thanks to
the FDA’s Zantac recall. So far,
the chemical has been linked with cancers of the:
- Small intestine
There is also reason to believe early-onset prostate cancer may be related
to NDMA exposure, as well as pancreatic cancer and 3 types of blood cancers:
leukemia, Non-Hodgkin’s lymphoma, and multiple myeloma. As research
continues, our team will stay up-to-date on the latest reports regarding
the hazards of NDMA exposure.
Do You Think Zantac Is Related to Your Cancer Diagnosis?
Now that solid evidence demonstrates the links between ranitidine-based
drugs (like Zantac) and NDMA, you could be able to file a claim if you
were diagnosed with one of the above cancers after taking these medications.
Our team can walk you through your legal rights and share the benefits
of filing a lawsuit. We’ve helped many clients get help after being
dangerous and defective drugs. No matter your situation, Richard Schwartz & Associates, P.A. can
fight for justice on your behalf.
Fighting Big Pharma in court isn’t easy, but the victims of these
companies’ negligence deserve justice. We can put our considerable
resources on your side to investigate your claim, find evidence and medical
authorities to testify on your behalf, and help you file a lawsuit against
any liable parties. Especially when it comes to treating cancer, receiving
compensation can make a big difference in your life.
Do you think Zantac or another ranitidine drug is to blame for your cancer?
Call our Mississippi attorneys today at (601) 869-0696 to schedule a